40 results about "Lipoprotein particle" patented technology

In vitro protein synthesis systems and methods are provided that produce membrane proteins in soluble form. In some aspects, the invention provides methods of synthesizing proteins using in vitro protein synthesis systems that include an apolipoprotein, in which higher yields of soluble protein are produced than in the absence of the apolipoprotein. Apolipoproteins useful in the present invention include naturally occurring apolipoproteins, as well as sequence variants of wild-type apolipoproteins, and engineered apolipoproteins. The apolipoproteins can be provided in an in vitro protein synthesis system associated with lipid or not associated with lipid. The invention also provides compositions and kits for synthesis of proteins in soluble form, in which the compositions and kits include cell extracts for protein translation and at least one apolipoprotein biomolecule.

This application discloses methods for assessing quantities of spherical or substantially spherical lipoprotein particles or portions thereof present in a biological sample based on the measurement of free cholesterol and / or phospholipid content in the lipoprotein particles. Methods of treating a subject at increased risk for cardiovascular disease and / or cardiodiabetes are also disclosed.

Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and / or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL / RHDL.

Non-naturally occurring receptor competent LDL particle comprising at least one peptide component wherein the said peptide component comprises at least a binding site for an Apo B protein receptor and at least one lipophilic substituent.

The invention relates to a process for preparing saposin lipoprotein particles, comprising a saposin-like protein, lipids and optionally a hydrophobic agent wherein the saposin-like protein or the hydrophobic agent is selectively bound to a support to allow the self-assembly of the saposin lipoprotein particles. The process of the invention comprises the step of a.) providing the hydrophobic agent and lipids, b. 1) / b.2) contacting the hydrophobic agent or the saposin-like protein with a support that is capable of selectively binding either of the two molecules to the support, c.1) / c.2) contacting the support-bound particle components with the remaining particle components, either the saposin-like protein or the hydrophobic agent, to allow fpr the self-assembly of the saposin lipoprotein particle on the support and d.) optionally eluting the support-bound saposin lipoprotein particles.

Nanostructures for the systemic delivery of nucleic acids, such as RNA, are provided herein. The nanostructures include templated lipoprotein nanoparticles (TLPs) composed of a core decorated with proteins, a lipid bilayer and hydrophobic molecules that self-assemble with nucleic acids, such as RNA. The nanostructures are useful for research, therapeutic and diagnostic applications.

An improved method of obtaining fluorescence measurements which may be used as a measure of the CETP-catalyzed rate of transfer of a lipophilic non-polar fluorescent cholesteryl ester between lipoprotein particles is disclosed. The method may be used in assays for screening CETP inhibitors.

A concentration of cholesterol ester or free cholesterol can be calculated using the concentrations of total cholesterol and triglyceride in lipoproteins contained in a sample. Further, a concentration of lipoprotein particles in a fraction can be calculated using the lipoprotein particle size in the fraction. The concentrations of total cholesterol and triglyceride contained in a subject sample are detected. Using the concentrations of total cholesterol and triglyceride thus detected, the concentration of cholesterol ester or free cholesterol is calculated. Further, using the concentration of cholesterol ester or free cholesterol thus calculated, the concentration of lipoprotein particles in a fraction can be calculated.

Non-naturally occurring lipoprotein particles, process for preparing such particles and uses thereof.

The invention discloses a reagent for detecting the concentration of lipoprotein particles. The reagent is composed of the following components: a diluent, a density liquid, and a buffer, and the density liquid contains alcohols, and the alcohols The concentration of the substance is 0.1%‑50%. The invention belongs to the field of in vitro diagnosis. The invention provides a reagent for detecting the concentration of lipoprotein particles. The reagent can detect the concentration of protein particles alone, and can be used in combination with other instrument reagents to simultaneously detect lipoprotein cholesterol subcomponents without having to detect twice, saving It saves time and cost, has high commercial value, and can be widely used in clinical tests and scientific research experiments.

Methods of decreasing, in a human or other animal, the susceptibility of atherogenic particles to aggregation induced by sphingomyelinase, the methods comprising administering vesicles to the animal.Also similar methods directed at the formation of cholesterol crystals, abnormal cholesterol enrichment of cell membranes, and denaturation of Apo B.

The invention is directed to a process for preparing a library of saposin lipoprotein particles, wherein the particles comprise membrane components from a cell or an organelle membrane and a lipid binding polypeptide that is a saposin-like protein belonging to the SAPLIP family of lipid interacting proteins or a derivative form thereof, wherein the process comprises the steps of a) providing a mixture of crude membrane vesicles obtained from a cell or an organelle membrane; b) contacting the mixture of step a) with the lipid binding polypeptide in a liquid environment; and c) allowing for self-assembly of the particles. The invention also provides a process for preparing a purified saposin lipoprotein particle comprising the steps of preparing a library according to the process described above and the additional step of f) purifying the saposin lipoprotein particle from the library. In addition, the invention provides a library of saposin lipoprotein particles and saposin lipoprotein particles obtainable according to the processes of the invention. These can be used in medicine, in particular in preventing, treating or lessening the severity of a disease or for use in a diagnostic method, a cosmetic treatment or for use as vaccination formulation or as a tool for drug development, drug screening, drug discovery, antibody development, development of therapeutic biologies, for membrane or membrane protein purification, for membrane protein expression, for membrane and / or membrane protein research, in particular lipidomics and proteomics, preferably for the isolation, identification and / or study of membranes and / or membrane proteins or creation of a lipidome or proteome database.